Cart
sales@molnova.com
SEB Domain 144-153
CAS No. 210229-94-0
SEB Domain 144-153( —— )
Catalog No. M30397 CAS No. 210229-94-0
This peptide is Staphylococcal Enterotoxin B domain amino acid residue 163-172. It has been shown to inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameSEB Domain 144-153
-
NoteResearch use only, not for human use.
-
Brief DescriptionThis peptide is Staphylococcal Enterotoxin B domain amino acid residue 163-172. It has been shown to inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1.
-
DescriptionThis peptide is Staphylococcal Enterotoxin B domain amino acid residue 163-172. It has been shown to inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number210229-94-0
-
Formula Weight1159.33
-
Molecular FormulaC50H90N14O17
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (86.26 mM)
-
SMILES——
-
Chemical NameSequence:{Lys}{Lys}{Lys}{Val}{Thr}{Ala}{Gln}{Glu}{Leu}{Asp}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
R?dstr?m KE, et al. Structure of the superantigen staphylococcal enterotoxin B in complex with TCR and peptide-MHC demonstrates absence of TCR-peptide contacts. J Immunol. 2014 Aug 15;193(4):1998-2004.
molnova catalog
related products
-
L-Homopropargylglyci...
L-Homopropargylglycine is an alkyl chain-based PROTAC linker utilized in the synthesis of PROTACs.
-
S-99
S-99 is a high purity chemical that targets ASK and is important for Immunology, Inflammation, Cancer research.
-
Linzagolix
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
